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1. Introduction 
Hodgkin’s lymphoma (HL) is currently recognized as B cell derived lymphoma with 
histological and biomarker-based distinction from other types of B cell derived lymphoma 
(Swerdlow, S.H. et al., 2008). HL had a worldwide incidence of 67,887cases in 2008, with an 
age standardized rate of 1.0 per 100,000 (both genders) (http://globocan.iarc.fr/). Some of the 
information in this chapter has already been part of an earlier review article (Banerjee, D., 
2011) and is cited again for the sake of completeness, but this chapter also provides some 
historical or current data that was not included that review. 
2. Historical aspects of Hodgkin’s Lymphoma 
The earliest description of Hodgkin’s lymphoma (HL) in an autopsy patient is attributed to 
Malpighi who described an 18 year old female with prominent splenic nodules in his 1666 
publication (Malpighi, M., 1666). Thomas Hodgkin, whose name is now associated with this 
disease, was very careful to mention this fact in the published version of his paper “On some 
morbid appearances of the absorbent glands and spleen” (Hodgkin, T., 1832) read to the Royal 
Medical and Chirurgical Society of London on January 10th and 24th, 1832. The paper was read 
not by Hodgkin but by the Society secretary Robert Lee. This was because Hodgkin was not a 
member of the Society at the time and therefore was prohibited from presenting the paper in 
person or even being present in the room during Lee’s reading of his paper.  
Although the compound microscope had been invented in 1590 by spectacle-makers 
Zacharias Janssen and his son Hans (Uluç, K. et al., 2009), its use in pathology was non 
existent in Malpighi’s time. It is thus impossible to verify that Malpighi had indeed 
described what we now recognize as Hodgkin’s lymphoma. Even Hodgkin, who actually 
knew about light microscopy, having used it in a study published with Lister (Hodgkin, T. 
& Lister, J.J., 1827), did not use a microscope to study this disease. This is due to the fact that 
tissue processing, staining, and histopathology were not established techniques at the time.  
Two of Hodgkin’s original 7 cases were subsequently proven to be true examples of 
Hodgkin’s lymphoma by Fox (Fox, H., 1926) and again by Poston, this time demonstrating 
that the neoplastic cells indeed expressed CD15 (Poston, R.N., 1999). Case IV is likely to be 
an example of a peripheral T cell lymphoma with rare CD15+ Reed Sternberg-like cells. It is 
possible the other 4 cases were also HL but no tissue was available for histology or 






Hodgkin’s description of his 7 cases remained in obscurity for years even after being 
rediscovered and attributed to him by Bright (Bright, R., 1838) and Wilks (Wilks, S., 1856). It 
was through Wilks’ persistence that the disease was later recognized as Hodgkin’s disease 
(Wilks, S., 1859). Wilks had to put the term “Hodgkin’s disease” in the title of his paper to 
make the point (Wilks, S., 1865). 
Most of the cases that Hodgkin described were patients who died soon after admission to 
hospital with terminal disease. He did have an opportunity to treat one of the 7 patients 
with cascarilla and soda to “improve his general health” and iodine “as an agent most likely 
to affect the glands” but noted dryly in his report that the treatment “appeared to be 
productive of no advantage, on which account it is probable the patient withdrew himself 
from my observation” (Hodgkin, T., 1832). 
The first description of the histopathological features of HL was published by Theodor 
Langhans, (Langhans, T., 1872). Six years later, Greenfield published the histopathological 
features of HL in the English language (Greenfield, W., 1878). The detailed description of the 
characteristic multinucleated cells in this disease was described by Carl Sternberg (Sternberg, 
C., 1898) and Dorothy Reed (Reed, D., 1902) and are now called Reed-Sternberg cells. Gall and 
Mallory established HL as a neoplastic process (Gall, E. & Mallory, T., 1942). The first 
definitive evidence of the neoplastic nature of HL came in 1967 with the publication about the 
cytogenetics of HL (Seif, G.S. & Spriggs, A.I., 1967), further supported by a 1975 publication 
that showed clonal growth of Hodgkin cells (Boecker, W.R. et al., 1975). 
The histopathological classification of HL has undergone several changes over the years. 
The first attempt to classify HL was by Jackson and Parker who in 1947 proposed three 
categories – paragranuloma, granuloma and sarcoma subtypes (Jackson, H. & Parker, F., 
1947). Smetana and Cohen published the results of a retrospective review of mortality rates 
of HL cases culled from the records of the Armed Forces Institute of Pathology, classified 
according to the Jackson and Parker classification (Smetana, H.F. & Cohen, B.M., 1956). They 
did not describe how these patients had been treated. 
Further refinement of HL classification came with the publications of Lukes and Butler 
(Lukes, R.J. et al., 1966; Lukes, R.J. & Butler, J.J., 1966), who divided HL into 6 groups: 
lymphocytic and/or histiocytic, (L & H), nodular, lymphocytic and/or histiocytic (L & H), 
diffuse, nodular sclerosis (NS), mixed, diffuse fibrosis and reticular. This was later 
simplified at the Rye Conference into 4 categories: Lymphocyte predominance (LP), 
Nodular sclerosis (NS), Mixed cellularity (MC), and Lymphocytic depletion (LD) (Lukes, R. 
et al., 1966). The first system to separate nodular lymphocyte predominance from classical 
HL was published in 1994 as part of the Revised European-American lymphoma (REAL) 
classification system, including the addition of a provisional entity of lymphocyte-rich 
classical HL (Harris, N.L. et al., 1994). The 2001 and 2008 WHO classification systems 
accepted the new category which is no longer a provisional one (Jaffe, E.S. et al., 2001; 
Swerdlow, S.H. et al., 2008).  Recently, a comprehensive update of the histopathology and 
immunohistochemistry findings in HL has been published (Eberle, F.C. et al., 2009). 
The therapy of HL has also undergone numerous changes, starting with Thomas Hodgkin’s 
attempts with cascarilla and soda and iodine combination therapy on one patient (Hodgkin, 
T., 1832). Fowler’s solution (potassium arsenite), a panacea concocted in 1786 by Thomas 
Fowler (Sears, D.A., 1988) for all sorts of chronic conditions, was used to treat HL (Waxman, 
S. & Anderson, K.C., 2001). It turns out that this was effective. In 1937 Hendrick and Burton 
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from the University of Toronto published a case report of a young male patient with HL 
who had a remarkable response to colloidal arsenic (Hendrick, A.C. & Burton, E.F., 1937). 
More recently, Mathas et al. have shown that sodium arsenite rapidly down regulates 
constitutive IĸB kinase (IKK) as well as NF-ĸB activity and induces apoptosis in Hodgkin 
Reed-Sternberg (HRS) cell lines containing functional IĸB proteins and that arsenic trioxide 
induces tumour reduction in xenograft models of HL (Mathas, S. et al., 2003). The use of 
nitrogen mustard for the chemotherapy of HL was  introduced by in 1946 (Goodman, L.S. et 
al., 1946), with reports from others on the results of nitrogen mustard on HL in the forties 
(Alpert, L.K. & Peterson, S.S., 1947; Dameshek, W. et al., 1949). 
Immunotherapy was attempted in 1928 (Wallhauser, A. & Whitehead, J.M., 1928). Three HL 
patients were treated with saline extracts from affected lymph nodes by subcutaneous 
injections. Two of the 3 patients achieved complete remission, while the third relapsed after 
initial response, but responded to a second round of injections.  This report encouraged 
Hanrahan to try the same approach in 1930 with 9 patients but with less spectacular results 
(Hanrahan, E.M., 1930). Hanrahan used a preservative, tricresol (a mixture of three isomeric 
phenols derived from toluene: ortho-, meta- or para-methylphenol), in the extract, so one 
could speculate that whatever the active substance was in the HL tissue extract might have 
been damaged by tricresol. 
Radiotherapy for HL was reported in 1932 (Chevalier, P. & Bernard, J., 1932) and firmly 
established as an effective therapeutic modality by Vera Peters of the Ontario Cancer 
Institute (Peters, M.V., 1960, 1965, 1966; Peters, M.V. & Middlemiss, K.C., 1958). 
Modern therapy of HL has been described in recent reviews (Boleti, E. & Mead, G.M., 2007; 
Edwards-Bennett, S.M. et al., 2010; Eichenauer, D.A. et al., 2009; Federico, M. et al., 2009; 
Mendler, J.H. et al., 2008; Oflazoglu, E. et al., 2008) and not further discussed here. 
3. The cell of origin and the pathobiology of HRS cells 
The neoplastic cells of classical HL (cHL) (Hodgkin/Reed-Sternberg cells or HRS cells) are 
usually derived from germinal centre B cells, and rarely are of T cell origin; those of nodular 
lymphocyte predominance (NLPHL) HL (LP cells) cases are always of germinal centre B cell 
origin (Brauninger, A. et al., 2006; Caporaso, N.E. et al., 2009; Kuppers, R., 2009; Küppers, R., 
2009; Kuppers, R. et al., 2002; Mani, H. & Jaffe, E.S., 2009; Marafioti, T. et al., 2000; Seitz, V. et 
al., 2000).  
Despite the fact that cHL HRS cells are derived from germinal centre or post-germinal centre 
B cells, they lack B cell markers including the B cell receptor (BCR) (Schwering, I. et al., 2003) 
as they lose their B cell programming (Hertel, C.B. et al., 2002) through several mechanisms 
including promoter DNA methylation (Doerr, J.R. et al., 2005; Ushmorov, A. et al., 2006), 
inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 resulting in 
reprogramming of neoplastic B cells (Mathas, S. et al., 2006), loss of PU.1 expression 
associated with defective immunoglobulin gene transcription (Jundt, F. et al., 2002), down-
regulation of BOB.1/OBF.1 and Oct2 (Stein, H. et al., 2001) and upregulation of NOTCH1, a 
negative regulator of the B cell program (Jundt, F. et al., 2008).  At the same time non-B cell 
lineage proteins are upregulated (Atayar, C. et al., 2005; Dorfman, D.M. et al., 2005).  
The LP cells in NLPHL are derived from antigen-activated germinal centre B cells 






(Mottok, A. et al., 2005; Schmitz, R. et al., 2009), BCL6 protein (Falini, B. et al., 1996), and 
GCET1 (centerin), a germinal centre B cell associated serpin (Montes-Moreno, S. et al., 2008). In 
contrast to H/RS cells, LP cells retain most of their B cell programming; however, LP cells also 
show selective loss of the B cell phenotype such as down regulation of CD19, CD37, PAG and 
LCK (Dogan, A. et al., 2000; Masir, N. et al., 2006; Tedoldi, S. et al., 2007). The mechanism is not 
related to promoter methylation of the encoding genes (Tedoldi, S. et al., 2007).  
3.1 The role of the Epstein Barr virus in HL 
The Epstein-Barr virus was first identified in 1964 by Epstein, Achong and Barr (Epstein, M. 
et al., 1964).  Up to 40-60% of cHL cases may contain the EBV genome (Kapatai, G. & 
Murray, P., 2007), but since EBV infects 90% of the adult population worldwide (Cohen, J., 
2000), and is a B lymphocytotropic virus, it may be a passenger, but not a driver in HL.  
Comprehensive EBV-human protein interaction maps have been generated by Calderwood 
et al. (Calderwood, M.A. et al., 2007) who showed over 40 interactions between EBV 
proteins and over 170 interactions between EBV and human proteins.  
4. Genetic defects in primary immunodeficiency disorders (PID) and HL 
Mutations in the SH2D1A and ITK genes are associated with aberrant T and NK function 
that predisposes patients to serious EBV infections, and lymphoproliferative disease 
including HL in those that survive the initial fulminant infectious mononucleosis. Detailed 
reviews of these PIDs has been published recently (Rezaei, N., Hedayat, M., et al., 2011; 
Rezaei, N., Mahmoudi, E., et al., 2011) and some key points are summarized below. 
4.1 SH2D1A  
The small (128-amino acid) Src homology 2 domain protein 1A (SH2D1A, DSHP or SAP) is  
associated with  X-linked lymphoproliferative disease (XLP). The patients respond to the 
Epstein-Barr virus (EBV) infection with a fulminant, frequently fatal infectious 
mononucleosis syndrome (Purtilo, D.T. et al., 1975; Rezaei, N., Mahmoudi, E., et al., 2011).  
Most cases of XLP are due to mutations in the SH2D1A gene, which codes for the adaptor 
molecule called Signaling Lymphocytic Activation Molecule (SLAM; CD150)-associated 
protein (SAP) (Rezaei, N., Mahmoudi, E., et al., 2011). Patients with XLP and Sap null mice 
have defective natural killer and CD8+ T cell cytotoxicity, impairment of T cell cytokine 
production, activation-induced cell death, germinal centre formation and T NK cell 
development (Rezaei, N., Mahmoudi, E., et al., 2011). Survivors may develop 
agammaglobulinemia and B cell malignant lymphomas including HL (Rezaei, N., Hedayat, 
M., et al., 2011; Seemayer, T.A. et al., 1995). SH2D1A has been detected in 5 of 6 EBV 
negative classical HL cell lines including T cell derived HL cell lines (Kis, L.L. et al., 2003) 
and SH2D1A mRNA  found in HRS cells in HL tissue (Nichols, K.E. et al., 1998). The lack of 
EBV in HL cell lines expressing SH2D1A protein is unexplained (Kis, L.L. et al., 2003). 
4.2 IL-2–inducible T-cell kinase (ITK) 
IL-2–inducible T-cell kinase (ITK) is a cytoplasmic non-receptor tyrosine kinase expressed in 
thymocytes,  mature T cells,  NK cells, iNKT cells, and mast cells (Au-Yeung, B.B. & Fowell, 
D.J., 2007; Au-Yeung, B.B. et al., 2006; Gadue, P. & Stein, P.L., 2002; Gomez-Rodriguez, J. et al., 
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2007; Grasis, J.A. et al., 2003; Iyer, A.S. & August, A., 2008; Qi, Q. et al., 2011). ITK mutations 
lead to fatal EBV induced lymphoproliferative disease characterized as hemophagocytic 
lymphohistiocytosis (HLH) and HL (Huck, K. et al., 2009; Stepensky, P. et al., 2011).  
5. Prognostic indicators derived from transcriptome, genome and host 
response patterns 
5.1 Gene copy number variation in HRS cells 
Complex chromosomal and genomic alterations occur in HRS cells of HL. My laboratory 
reported novel gains and losses of 9 novel regions in Hodgkin Lymphoma cell lines L428 
and KMH2, which shared gains in chromosome cytobands 2q23.1-q24.2, 7q32.2-q36.3, 
9p21.3-p13.3, 12q13.13-q14.1, and losses in 13q12.13-q12.3, and 18q21.32-q23. The genes 
located in  these regions include cell cycle associated genes, MAPK signaling pathway 
genes, those encoding tight junction proteins, Jak/Stat signaling pathway genes and tumour 
suppressor gene ING3 (Fadlelmola, F. et al., 2008). 
Steidl et al. compared patients that had failed primary treatment with those that responded 
as usual (Steidl, C., Telenius, A., et al., 2010). Gains of 16p11.2-13.3 were associated with 
treatment failure and shorter disease-specific survival. One of the genes mapping to this 
region is the multidrug resistance gene ABCC1 encoding multidrug resistance protein MRP1 
(Leslie, E. et al., 2001; Rosenberg, M. et al., 2001), and functional studies indicate that this 
does play a  role in chemoresistance (Steidl, C., Telenius, A., et al., 2010).  
5.2 Gene expression studies 
Devilard et al. using whole cells including the microenvironment, found a signature that can 
distinguish between good outcome Hodgkin's disease and bad outcome cases (Devilard, E. 
et al., 2002). Good outcome was associated with overexpression of genes involved in 
apoptotic induction and cell signaling pathways, including cytokines, whereas bad outcome 
was associated with overexpression of genes associated with fibroblast activation, 
angiogenesis, extracellular matrix remodeling, cell proliferation, and the down regulation of 
tumor suppressor genes.  
Sánchez-Aguilera et al. identified 145 genes predictive of outcome (Sanchez-Aguilera, A. et 
al., 2006). Four different signatures were obtained by supervised hierarchical clustering, 2 of 
which were associated with the host immune response of tumor microenvironment and the 
other 2 with the HRS cells based on known expression in HL cell lines and normal germinal 
centre B cells.  
Chetaille et al. studied 63 cHL cases (not enriched for HRS by microdissection, thus 
including cells from the microenvironment) using full transcriptome coverage  and found 47 
genes associated with adverse outcome, and 403 genes associated with favorable outcome 
(Chetaille, B. et al., 2009). Favorable outcome was associated with expressed genes of the “B-
cell” cluster, whereas genes associated with unfavorable outcome were in the “extracellular 
matrix” cluster. 
Global gene expression analysis of microdissected LP cells (L&H cells) from 5 cases of 






signatures were closer to T cell-rich B cell lymphoma and classical HL than to diffuse large B 
cell lymphoma, Burkitt lymphoma, and follicular lymphoma. There is increased expression 
of ABCC1 in LP cells, which as already discussed, encodes multidrug resistance protein 
MRP1 (Leslie, E. et al., 2001) and is also amplified and overexpressed in primary treatment 
refractory cHL (Steidl, C., Telenius, A., et al., 2010). 
5.3 Host microenvironment/immune response  
An increased number of CD68+ macrophages is associated with a shortened progression-
free survival, an increased risk of relapse after HDCT/ASCT, and shortened disease-specific 
survival. In multivariate analysis, CD68+ cells as a prognostic factor is superior to the 
International Prognostic Score for disease-specific survival. The absence of an increased 
number of CD68+ cells in patients with limited-stage disease predicted long-term disease-
specific survival of 100% in cHL patients treated with current treatment protocols (Steidl, C., 
Lee, T., et al., 2010). The immunohistochemistry (IHC) assay for CD68, which is widely 
available in clinical laboratories, can identify patients with HL who are likely to be 
refractory to first line therapy and was noted to be the first predictive in-vitro test for cHL 
(DeVita, V.T., Jr. & Costa, J., 2010).  
5.4 Mechanisms of chemoresistance 
The multidrug resistance gene ABCC1 in overexpressed in LP and HRS cells and HRS cells 
contain increased copy number of the ABCC1 gene (Brune, V. et al., 2008; Steidl, C., 
Telenius, A., et al., 2010). HL tumor samples contain a population of cells that increase efflux 
of Hoechst 33342 dye and are resistant to gemcitabine, a commonly used drug for the 
treatment of refractory HL. These cells have the phenotype of HRS cells and express 
multidrug resistance genes ABCG2 and MDR1 (ABCB1) (Shafer, J.A. et al., 2010).  
Genes encoding cytokine receptors (IL5RA, IL13RA1), markers expressed on antigen-
presenting cells (CD40, CD80), as well as genes with known association to chemoresistance, 
such as myristoylated alanine-rich protein kinase C substrate, and PRAME (preferentially 
expressed antigen in melanoma) are upregulated in chemoresistant cells (Staege, M.S. et al., 
2008). 
Chemoresistance in HL is also related to XIAP (X-linked inhibitor of apoptosis) an NF-
kappaB-independent target of bortezomib. Bortezomib sensitizes HL cells against a variety 
of cytotoxic drugs independent of NF-kappaB (Kashkar, H. et al., 2007).  
6. How the HRS cell, an abnormal B cell clone, survives the normal apoptotic 
process and immune destruction 
Normally B cells that fail to achieve productive or high affinity Ig gene rearrangements or 
lack BCR are destroyed during the germinal centre reaction (Gordon, J. et al., 1993; Guzman-
Rojas, L. et al., 2002; Hollowood, K. & Goodlad, J.R., 1998; Zhang, Q.P. et al., 2005). There are 
several excellent reviews on the topic of the germinal centre reaction and mechanisms of B 
cell apoptosis and survival during a normal antigen driven reaction (Elgueta, R. et al., 2010; 
Goodnow, C.C. et al., 2010; Nutt, S.L. & Tarlinton, D.M., 2011; Oracki, S.A. et al., 2010; 
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Vikstrom, I. & Tarlinton, D.M., 2011; Vinuesa, C.G. et al., 2010), so only a brief summary is 
provided in this chapter.  
6.1 The germinal center reaction 
The biologic or physiologic purpose of the germinal centre reaction is to generate long-term 
humoral immunity in the adaptive immune system against antigens expressed by 
pathogens, while, at the same time, eliminating autoreactive clones. The end result is the 
generation of long-lived antibody-secreting plasma cells and memory B cells which can 
rapidly trigger subsequent waves of plasma cell production when the same antigen/s are 
encountered again. The germinal centre reaction is a complex cascade of events, highly 
regulated, requiring crosstalk and collaboration between B cells, follicular helper T cells and 
antigen presenting cells including dendritic cells, macrophages and follicular dendritic cells 
(Cattoretti, G. et al., 2005; Elgueta, R. et al., 2010; Guzman-Rojas, L. et al., 2002; Jardin, F. et 
al., 2007; Kosco-Vilbois, M.H., 2003; Park, C.S. & Choi, Y.S., 2005; Phan, R.T. & Dalla-Favera, 
R., 2004; Schenka, A.A. et al., 2005; Siepmann, K. et al., 2001; Spender, L.C. et al., 2009; 
Tarlinton, D.M. & Smith, K.G., 2000; Zhang, Q.P. et al., 2005). 
6.2 The primary lymphoid follicle 
Primary lymphoid follicles appear in the second trimester of fetal life in humans and are 
composed of antigen-naive recirculating B cells that migrate through meshworks of 
follicular dendritic cells (FDC) with a transit time of 24 hours (Howard, J.C. et al., 1972). 
These antigen-naive B cells have already undergone recombination of gene fragments, with 
a theoretical repertoire of >1010 antigen binding receptors (Berek, C. & Milstein, C., 1988). 
When these B cells encounter an antigen, they increase their expression of the chemokine 
receptor CCR7 which facilitates their migration to the interface between T and B cells zones 
(Cyster, J.G., 2005; Okada, T. & Cyster, J.G., 2006). Here they can contact antigen-primed T 
cells, triggering a burst of proliferation of the activated B cells in the outer follicle, ultimately 
forming a germinal centre (Coffey, F. et al., 2009). HRS cells of cHL also express CCR7 which 
may explain why HRS cells tend to be located in interfollicular zones (Höpken, U.E. et al., 
2002). LP cells are CCR7- and therefore remain in germinal centers. 
6.3 Somatic hypermutation – Generation of higher affinity antibodies 
Activated B cells undergo a process of affinity maturation in the germinal center reaction. 
Rearranged immunoglobulin (Ig) variable region genes undergo random point mutations by 
a process called somatic hypermutation (SHM) in which single nucleotide substitutions are 
introduced at a rate of one mutation per 1000 base pairs per generation (Berek, C. & 
Milstein, C., 1988).  Both LP cells of NLPHL and HRS cells of cHL show evidence of SHM of 
Ig variable region genes (Liso, A. et al., 2006) and are therefore considered to be derived 
from antigen-activated B cells. 
6.4 Selection of high affinity B cells 
Since SHM is a random process, a wide range of antigen-binding affinities may result. A 






selected is required for optimal function. The default event seems to be death by apoptosis 
through the Fas/CD95 pathway unless the cells are rescued by signals from other cell types. 
Fas/CD95 triggers elimination of low-affinity and self-reactive B cell clones that arise during 
the germinal centre reaction through apoptosis (Defrance, T. et al., 2002). Prior to apoptosis, 
rapid activation of caspase-8 occurs in association with CD95 death-inducing signaling 
complex (DISC). c-FLIP(L), which protects B cells from Fas/CD95 triggered apoptosis is 
rapidly lost from the CD95 DISC unless the B cells are exposed to the survival signal 
provided by CD40L from follicular T helper cells (Hennino, A. et al., 2001). In cHL, over 80% 
of cases show constitutive expression of c-FLIP which protects the HRS cells from Fas/CD95 
triggered apoptosis without the need for CD40L survival signals (Mathas, S. et al., 2004; 
Thomas, R. et al., 2002; Uherova, P. et al., 2004). 
6.5 The role of the follicular helper T cell (TFH) 
The localization of T cells coexpressing HNK-1 (CD57) in the germinal centers (GC) of 
lymph nodes and spleens was reported by my laboratory (Banerjee, D. & Thibert, R.F., 
1983). Although expressing HNK-1 (CD57), which was initially thought to be human natural 
killer cell specific, these cells were not cytotoxically active. Under certain circumstances, we 
found that these cells could either suppress or enhance immunoglobulin production by 
pokeweed mitogen-activated tonsillar B cells (Banerjee, D. et al., 1988). Such cells are now 
recognized to be specialized CD4+ T cells called follicular helper T cells (TFH) that home to 
the germinal center and play a pivotal role in regulating the fate of B cell in the germinal 
centre reaction. They express cell surface antigens CD4, CD57, and CXCR5, produce IL-21, 
IL-6, IL-27, BCL-6, ICOS, CD40L, and PD-1 (Crotty, S., 2011). While germinal centre CD57+ 
CD4+ T cells have been shown to be a major T helper cell subset for GC-B cells in Ig 
synthesis, and have the capacity to induce activation-induced cytosine deaminase (AID) and 
class switch recombination (Kim, J.R. et al., 2005), the most effective subset of capable of 
inducing IgG production is the CXCR5hi  ICOShi  CD4+ T cell. The presence or absence of 
CD57 does not appear to affect this function (Rasheed, A.U. et al., 2006).  
Cells with the phenotype of TFH are usually found in contact with of NLPHL LP cells (Nam-
Cha, S.H. et al., 2009) forming characteristic rosettes. The expression of PD-1 is more 
frequent than that of CD57 by the T cell rosettes around LP cells (Churchill, H.R. et al., 2010). 
PD-1+ T cells are also reported in cHL and HRS cells express both ligands for PD-1 (CD279), 
B7-H1 (PDL1; CD274) and B7-DC (PDL2; CD273) (Yamamoto, R. et al., 2008). The function 
of PD-1+ T cells  in HL is unknown. In normal germinal center reactions, PD-1 signals 
enhance B cell survival (Good-Jacobson, K.L. et al., 2010), thus it is possible that PD-1+ TFH 
cells in both NLPHL and cHL provide additional survival signals. Another  protective effect 
of PD-1 could be mediated through its inhibition of cytotoxic T cells via overexpressed PD-1 
ligands CD273 or CD274 by the target cells of cytotoxic T cells (Norde, W.J. et al., 2011).  
6.6 IL-21 
HRS cells aberrantly express IL-21 and the IL-21 receptor. IL-21 activates STAT3 in HRS 
cells, up-regulates STAT3 target genes, and protects HRS cells from CD95 death receptor–
induced apoptosis. In addition, IL-21 through up-regulation of the CC chemokine 
macrophage-inflammatory protein-3α (MIP-3α) attracts CCR6+CD4+CD25+FoxP3+CD127lo 
regulatory T cells to migrate close to the proximity of HRS cells, protecting them from 
immune attack (Lamprecht, B. et al., 2008). 
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IL-6 is a pleiotropic cytokine (also called B-cell stimulatory factor-2, IFN-b2, 26-kDa protein, 
Hybridoma/plasmacytoma growth factor and hepatocyte stimulating factor HSF) with 
biological activities in immune regulation, hematopoiesis, inflammation and neoplasia 
(Kishimoto, T., 2010). HL cells express multiple cytokines, including interleukin-6 (IL-6) 
(Tesch, H. et al., 1992). Increased serum levels are associated with advanced disease and 
worse prognostic scores (Vener, C. et al., 2000). HL cells produce IL-6 through constitutional 
activation of the PI3K signaling pathway which promotes expression of HLXB9, an EHG 
homeobox gene family member, which in turn activates IL6 (Nagel, S. et al., 2005). Thus HL 
cells, and presumably HRS cells in vivo, do not solely depend upon TFH for IL-6 supply but 
make their own, possibly benefiting from an autocrine loop. 
6.8 BCL-6 
The BCL6 proto-oncogene encodes a nuclear transcriptional repressor. It is important in 
germinal center (GC) formation and regulates lymphocyte function, differentiation, and 
survival. BCL-6 suppresses p53 in GC B-cells and protects B-cell lines from apoptosis 
induced by DNA damage. BCL-6 is thought to allow GC B-cells to sustain the low levels of 
physiological DNA breaks related to somatic mutation (SM) and immunoglobulin class 
switch recombination (Jardin, F. et al., 2007). BCL-6 is also an important regulator of the TFH 
cell program, being essential for CXCR5 expression and follicular homing by TFH cells (Yu, 
D. et al., 2009). 
BCL-6 expression is usually seen in NLPHL and about 30% of lymphocyte rich classical HL 
(LRCHL)  but not other forms of cHL (Nam-Cha, S.H. et al., 2009). However, in another 
study, none of the cases of LRCHL expressed BCL-6 (Brauninger, A. et al., 2003). 
6.9 Bfl-1 
Bfl-1 is a NF-κB target gene from the Bcl-2 family of apoptosis-regulating proteins. Bfl-1 is 
expressed in HRS cells in clinical biopsies and also expressed in HL cell lines. Bfl-1 can 
protect cultured H/RS cells from apoptosis induced by pharmacological inhibitors of NF-κB 
(Hinz, M. et al., 2001; Loughran, S.T. et al., 2011).  
7. Next generation whole genome sequencing and new insights into the 
pathobiology of HL 
Technological improvements now allow the analysis of entire genomes and transcriptomes 
at a sufficient resolution to detect point mutations at high speed and reduced cost (Cronin, 
M. & Ross, J.S., 2011). Two recent discoveries that are relevant to HL are highlighted in this 
review. 
7.1 MHC class II transactivator CIITA, PD-1 and PD-1 ligands  
In 15% of cHL, a gene fusion involving the major histocompatibility complex (MHC) class II 
transactivator CIITA (MHC2TA) and several partners has been reported (Steidl, C. et al., 






with downregulation of HLA Class II  expression which could help HRS cells evade 
immunosurveillance, CIITA also fuses with genes encoding CD274 (PDL1) and CD273 
(PDL2), leading to overexpression of both these PD-1 ligands by HRS cells. This could have 
two beneficial effects on HRS cell survival, the first through PD-1 survival signals from TFH 
cells to the neoplastic B cells and the second through inhibition of cytotoxic T cells as 
already discussed above. 
7.2 EZH2  
Mutations in EZH2, a polycomb group oncogene which encodes a histone 
methyltransferase, have been described in follicular lymphomas and diffuse large B cell 
lymphomas of germinal centre type. These mutations involve a single tyrosine (Y641) in the 
SET domain of the EZH2 protein reducing its enzyme action (Morin, R.D. et al., 2010). While 
HL cases were not included in this study, this protein may have a role in HL. Whereas the 
expression of the polycomb group gene encoded proteins BMI-1 and EZH2 genes is 
associated with resting or proliferating germinal centre B cells, respectively and not 
coexpressed, Hodgkin/Reed-Sternberg (H/RS) cells co-express BMI-1 and EZH2 (Dukers, 
D.F. et al., 2004; Raaphorst, F.M. et al., 2000).  
8. New targets for potential therapeutic approaches 
CD20, a B cell expressed phosphoprotein, is usually expressed by LP cells in NLPHL but 
variably positive in a minority of cHL cases as recently reviewed by Saini and others (Saini, 
K.S. et al., 2011). Despite CD20 negativity in most cases of cHL, patients refractory to all 
conventional HL therapies have responded to rituximab (Younes, A. et al., 2003).  An excellent 
review of the myriad of potential targets for novel therapies for treatment refractory HL has 
been published by Younes (Younes, A., 2009), and some of these, and the rationale for their use 
have been summarized in one of my recent review articles (Banerjee, D., 2011). 
My laboratory recently reported that a 21 kDa protein (Zhou, M. et al., 2008), which we 
subsequently identified as CYB5B, an outer mitochondrial membrane protein, is 
overexpressed in the cytoplasm and plasma membrane of HRS cells but not at the plasma 
membrane of normal reactive lymphocytes or bone marrow precursor cells (Murphy, D. et 
al., 2010). Gains in the CYB5B locus in HL cell lines KMH2 and L428 were detected. HL cell 
lines show increased CYB5B mRNA but reactive lymphocytes and bone marrow precursor 
cells show no increase in CYB5B mRNA in comparison to housekeeping genes. Due to its 
location at the plasma membrane of only neoplastic cells in cHL, diffuse large B cell 
lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL), CYB5B might be an 
attractive target for antibody based therapy as toxicity should be minimal since we have 
determined that normal, reactive lymphocytes and CD34+ bone marrow precursor cells do 
not express the protein at the plasma membrane (Murphy, D. et al., 2010). We are in the 
process of creating chimeric antibodies to determine whether they are effective in killing 
HRS cells in pre-clinical models. 
9. Discussion 
From Hodgkin’s first report in 1832 on what we now call Hodgkin’s Lymphoma, to this day, 
the pathobiology of HL continues to intrigue and  surprise us with the myriad ways in 
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which the LP and HRS cells defy all physiologic rules of B cell survival by exploiting the 
very signals that would normally stop undesirable B cells from surviving. The vast network 
of crosstalk and redundancy of pathways the tumour cells have successfully utilized keeps 
growing in complexity. These observations challenge our preconceived notions of cell 
lineage fidelity as defined by expressed cell surface proteins and other biomarkers. Indeed 
reprogramming and plasticity of B cells is a reality, thus neoplastic B cells derived from the 
germinal centre can assume various “identities” and confuse regulatory cells and pathways 
(Mathas, S., 2007). Eventually, classification of B cell lymphomas including HL will require, 
not just lineage determination and morphology-based classification and grading, but also 
the detailed mapping of  aberrant pathways in sufficient resolution for us to understand all 
the potential nodes that could be novel therapeutic targets. 
10. Conclusion 
HL is a unique set of B cell lymphomas that are characterized by the exploitation of 
redundant pathways, and crosstalk between regulatory cells that promote the growth and 
survival of defective B cells which, under normal conditions, would die during the germinal 
centre reaction. While this may seem an insurmountable level of complexity, the potential 
for effective novel targeted therapies to deal with refractory disease will be possible to attain 
when a comprehensive map of pathway pathology is feasible in the future. 
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